pharmaphorum7d
AbbVie closes on Rinvoq approval in inflamed artery disease
JAK inhibitor Rinvoq (upadacitinib) has been backed by the CHMP as a 15mg, once-daily treatment for adults with GCA, an ...
3 Cheap Stocks to Buy With Your Tax Refund Check
Investing some of your tax refund in stocks can help build your portfolio. The three stocks below trade at forward earnings ...
Zacks Investment Research on MSN2d
Here's How to Play AbbVie Stock as it Enters the Obesity Space
AbbVie ABBV announced that it is in-licensing rights to develop phase I candidate, GUB014295, a long-acting amylin analog for ...
Crain's Chicago Business6d
Europe poised to OK another use for AbbVie's Rinvoq
Right now, Rinvoq is approved in the European Union and the U.S. for the treatment of adults with radiographic axial ...
AbbVie Gets CHMP Backing of Rinvoq in Giant Cell Arteritis
AbbVie said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with ...
AbbVie Steps Into The Ring In The Obesity Drug Wars
AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...
AbbVie's Next Big Moneymaker? This Drug Just Took a Huge Step Toward Approval
A key regulatory win could turn this under-the-radar treatment into AbbVie's next billion-dollar success story.
Morningstar7d
AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis
AbbVie. "We are committed to advancing the standards of care for immune-mediated diseases and addressing unmet patient needs, today and in the future." RINVOQ is approved in the European Union ...